Title:
TLR INHIBITORY OLIGONUCLEOTIDES AND THEIR USE
Document Type and Number:
WIPO Patent Application WO/2017/111045
Kind Code:
A1
Abstract:
The inhibitory oligonucleotides with partial phosphorothioation with reduced toxicity strongly block NF-kB activation induced by TLR9 agonists and TLR7/8 agonists. The production of proinflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFa), is inhibited by the inhibitory-oligonucleotides. Interferon (IFN) production from human PBMC induced by TLR9 agonist is prevented by the inhibitory-oligonucleotides. These oligonucleotides can be used as a remedy for the treatment of immune-mediated disorders such as rheumatoid arthritis, systemic lupus erythematosus (SLE), sepsis, multiple organ dysfunction syndromes and inflammatory cytokine-mediated inflammatory disease.
Inventors:
ESASHI EIJI (JP)
ISHIDA KOJI (JP)
HOSOZAWA TAKUMI (JP)
OKUYAMA MEGUMI (JP)
KOTAKI AYUMI (JP)
ISHIDA KOJI (JP)
HOSOZAWA TAKUMI (JP)
OKUYAMA MEGUMI (JP)
KOTAKI AYUMI (JP)
Application Number:
PCT/JP2016/088418
Publication Date:
June 29, 2017
Filing Date:
December 22, 2016
Export Citation:
Assignee:
SBI BIOTECH CO LTD (JP)
International Classes:
C12N15/117; A61K31/7088; A61P37/02
Domestic Patent References:
| WO2014082254A1 | 2014-06-05 | |||
| WO2006105361A2 | 2006-10-05 | |||
| WO2005101968A2 | 2005-11-03 |
Foreign References:
| US20100035972A1 | 2010-02-11 |
Other References:
GOLDSBY ET AL.: "Immunology", 2003, W.H. FREEMAN AND COMPANY
"The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5", N ENGL J MED, vol. 353, 2005, pages 1374 - 85
See also references of EP 3394263A4
"The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5", N ENGL J MED, vol. 353, 2005, pages 1374 - 85
See also references of EP 3394263A4
Attorney, Agent or Firm:
ASAMURA PATENT OFFICE,P.C. (JP)
Download PDF: